Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is an oral, direct-acting, reversible P2Y12 receptor antagonist used to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) or a history of myocardial infarction.
## Primary Indications
* Reduction of thrombotic cardiovascular events in patients with ACS (unstable angina, non-ST-elevation myocardial infarction, or ST-elevation myocardial infarction).
* Prevention of thrombotic events in patients with a history of myocardial infarction (MI) and at least one additional risk factor for cardiovascular events.
## Adult Dosing
* **ACS:** 180 mg orally once as a single loading dose, followed by 90 mg orally twice daily.
* **Post-MI (with risk factors):** 60 mg orally twice daily.
* **Duration of therapy:** Typically 12 months, but duration can vary based on individual patient risk and clinical judgment.
## Pediatric Dosing
There is no established pediatric dosing for ticagrelor.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment is recommended. However, ticagrelor has not been studied in patients with severe renal impairment.
* **Hepatic Impairment:** No dose adjustment is recommended. However, ticagrelor has not been studied in patients with severe hepatic impairment.
## Contraindications
* Known hypersensitivity to ticagrelor or any of its excipients.
* Active pathological bleeding.
## Adverse Effects
* **Common:** Dyspnea, bruising, bleeding (including fatal or life-threatening bleeding), diarrhea, headache, rash.
* **Serious:** Major bleeding, ventricular pauses (bradyarrhythmias).
## Key Drug Interactions
* **CYP3A4 Inhibitors/Inducers:** Ticagrelor is a substrate of CYP3A4. Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) may increase ticagrelor concentrations. Concomitant use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine) may decrease ticagrelor concentrations.
* **Aspirin:** Aspirin is generally recommended to be co-administered with ticagrelor for ACS, but the optimal dose of aspirin is not definitively established and may vary by local protocol. Higher doses of aspirin may increase bleeding risk.
* **Other Antithrombotics:** Concomitant use with other antithrombotic agents (e.g., warfarin, other P2Y12 inhibitors, NSAIDs) increases the risk of bleeding.
## Monitoring
* Monitor for signs and symptoms of bleeding (e.g., hematuria, melena, epistaxis, bruising).
* Monitor for dyspnea.
* ECG monitoring for ventricular pauses may be considered, especially in patients with pre-existing risk factors.
## Clinical Pearls
* Ticagrelor is a reversible P2Y12 inhibitor, meaning its effect can be more rapidly reversed compared to clopidogrel if urgent surgery is required.
* Patients may experience an increase in uric acid levels and/or serum creatinine.
* Ticagrelor has a black box warning for increased bleeding risk.
* The 180 mg loading dose is crucial for initiating therapy in ACS.
* Dyspnea is a common side effect, which may not necessarily be related to cardiac issues.
***
*This information is intended for healthcare professionals and does not replace the need to consult the official prescribing information or relevant guidelines.*
